Abstract

Until recently, most systematic studies in bipolar disorder concentrated on reduction of illness severity as the primary outcome measure. However, functional disabilities even in euthymic phases are a key issue [1] and improving quality of life in different domains as work, family and social activities appears to be of utmost importance for patients as a recent WHO survey shows. Especially in bipolar depression, functionality of patients appears severely impaired throughout several domains [2]. As demonstrated by Hirschfeld et al. [3] this impairment appears more severe in bipolar compared to unipolar depression. Thus, not only reducing depressive symptomatology but also improving quality of life should be a primary target for any new treatment option, both pharmacological and non-pharmacological. Psychotherapy, even just psychoeducation, can clearly improve coping with the illness and by this also improve quality of life [4]. In addition, some new pharmacological treatment options as the atypical antipsychotic quetiapine could demonstrate that they are not only improving depressive symptomatology in bipolar depression, but also significantly improve quality of life as measured with the Q-LESQ (Quality of Life Enjoyment and Satisfaction Questionnaire: 16-item short form [5]).

Highlights

  • en/p1I7n4te4r-n8a5t9ioXn-a5l-S1o-cfiueltl.ypdofn">Bhrearine.Burional Congress on Brain and Behaviour Meeting abstracts – A single PDF containing all abstracts in this Supplement is available

  • In bipolar depression, functionality of patients appears severely impaired throughout several domains [2]

  • Reducing depressive symptomatology and improving quality of life should be a primary target for any new treatment option, both pharmacological and non-pharmacological

Read more

Summary

Introduction

en/p1I7n4te4r-n8a5t9ioXn-a5l-S1o-cfiueltl.ypdofn">Bhrearine.Burional Congress on Brain and Behaviour Meeting abstracts – A single PDF containing all abstracts in this Supplement is available

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.